Active substance
Cilazapril
- SFDA 3
- Health Canada 6
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| INHIBACE 1MG TAB | 1 mg | Tablet · Oral use | 30 Blister | SAR 39.00 | NCE · Prescription | ROCHE | Withdrawn by MAH · Not Marketed |
| INHIBACE 2.5MG TAB | 2.5 mg | Tablet · Oral use | 28 Blister | SAR 53.95 | NCE · Prescription | ROCHE | Withdrawn by MAH · Not Marketed |
| INHIBACE 5MG TAB | 5 mg | Tablet · Oral use | 28 Blister | SAR 67.75 | NCE · Prescription | ROCHE | Withdrawn by MAH · Not Marketed |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-CILAZAPRIL | 02291142 | 2.5 MG | TABLET · ORAL | APOTEX INC |
| APO-CILAZAPRIL | 02291150 | 5 MG | TABLET · ORAL | APOTEX INC |
| INHIBACE | 01911481 | 5 MG | TABLET · ORAL | CHEPLAPHARM ARZNEIMITTEL GMBH |
| MYLAN-CILAZAPRIL | 02283778 | 1 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-CILAZAPRIL | 02283786 | 2.5 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-CILAZAPRIL | 02283794 | 5.0 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.